Post job

Imprimis Pharmaceuticals main competitors are Gilead Sciences, Acorda Therapeutics, and Medivation.

Competitor Summary. See how Imprimis Pharmaceuticals compares to its main competitors:

  • Merck has the most employees (74,000).
  • Employees at Gilead Sciences earn more than most of the competitors, with an average yearly salary of $99,828.
Work at Imprimis Pharmaceuticals?
Share your experience

Imprimis Pharmaceuticals vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1998
4.4
San Diego, CA2$48.9M143
1891
4.6
Kenilworth, NJ31$64.2B74,000
2003
4.8
San Francisco, CA1$1.0B628
1987
4.5
Foster City, CA9$28.8B11,800
1954
4.8
New York, NY1$3.6B6,200
1919
4.7
Maple Grove, MN4$420.0M550
1998
4.8
Gaithersburg, MD12$1.6B1,834
1992
4.9
Rockville, MD1$131.0M1,000
1995
4.6
Ardsley, NY3$117.6M344
1994
4.2
Lake Mary, FL1$18.0M378
2005
4.3
Coppell, TX1$34.9M291
Affinity Health
-
4.7
Appleton, WI1$4.0M15
2001
4.1
Andover, MA1$70.6M202
1987
4.4
Elk Grove Village, IL1$405.0M750
2007
4.3
Nashville, TN1$12.5M44
1994
4.3
Farmers Branch, TX12$280.0M3,000
1996
4.6
Somers Point, NJ1$50.0M500
2013
4.4
Hatboro, PA1$110.0M950
-
3.6
Orlando, FL1$5.4M3,000
1972
3.8
Vancouver, WA1$16.4M50
1999
4.8
Tukwila, WA11$520.6M1,700

Rate Imprimis Pharmaceuticals' competitiveness in the market.

Zippia waving zebra

Imprimis Pharmaceuticals salaries vs competitors

Among Imprimis Pharmaceuticals competitors, employees at Gilead Sciences earn the most with an average yearly salary of $99,828.

Compare Imprimis Pharmaceuticals salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Imprimis Pharmaceuticals
$62,221$29.91-
Merck
$90,328$43.43-
Medivation
$94,135$45.26-
Gilead Sciences
$99,828$47.99-
Forest Laboratories
$91,901$44.18-
Upsher-Smith Laboratories
$63,937$30.74-

Compare Imprimis Pharmaceuticals job title salaries vs competitors

CompanyHighest salaryHourly salary
Imprimis Pharmaceuticals
$39,716$19.09
Merck
$48,675$23.40
Gilead Sciences
$47,443$22.81
Acorda Therapeutics
$43,079$20.71
Upsher-Smith Laboratories
$41,527$19.96
Forest Laboratories
$41,268$19.84
Emergent BioSolutions
$40,396$19.42
Human Genome Sciences
$39,719$19.10
Medivation
$38,280$18.40
Philidor Rx Services
$37,402$17.98
Acariahealth, Inc.
$36,692$17.64
CCS Medical
$36,634$17.61
Affinity Health
$36,485$17.54
CuraScript SD
$36,468$17.53
Injured Workers Pharmacy
$36,374$17.49
Orsini Specialty Pharmacy
$36,366$17.48
Home Infusion Solutions
$36,247$17.43
Davita Rx
$36,203$17.41
Vancouver Radiologists
$36,144$17.38
NuScriptRX
$36,104$17.36

Do you work at Imprimis Pharmaceuticals?

Is Imprimis Pharmaceuticals able to compete effectively with similar companies?

Imprimis Pharmaceuticals jobs

Imprimis Pharmaceuticals demographics vs competitors

Compare gender at Imprimis Pharmaceuticals vs competitors

Job titleMaleFemale
CCS Medical31%69%
Merck54%46%
Emergent BioSolutions56%44%
Gilead Sciences56%44%
Acorda Therapeutics58%42%
Imprimis Pharmaceuticals--

Compare race at Imprimis Pharmaceuticals vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
58%17%11%11%3%
9.4
60%11%16%9%4%
9.6
44%20%8%23%6%
9.8
56%16%10%14%4%
9.8
60%16%15%6%3%
8.8
65%14%10%8%4%
9.4

Imprimis Pharmaceuticals revenue vs competitors

Imprimis Pharmaceuticals revenue is $48.9M. Among it's competitors, the company with the highest revenue is Merck, $64.2B . The company with the lowest revenue is Affinity Health, $4.0M.

Imprimis Pharmaceuticals and similar companies CEOs

CEOBio

Ron Cohen, M.D., President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp. He previously served as Director and Chairman of the New York Biotechnology Association (NYBA). He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. He is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA “The Cure Starts Here” Business Leader of the Year.

Robert Kramer Sr.
Emergent BioSolutions

Robert Kramer is a President & Chief Executive Officer at EMERGENT BIOSOLUTIONS INC., Board Member at EMERGENT BIOSOLUTIONS INC., and Interim Exec VP:Services at EMERGENT BIOSOLUTIONS INC. and is based in Lansing, Michigan. He has experience at PHARMACIA CORP and has worked as Pres:Biosciences Div at EMERGENT BIOSOLUTIONS INC., Consultant at EMERGENT BIOSOLUTIONS INC., and President at Emergent Biodefense Ops Lansg. Robert works or has worked as Chief Executive Officer at Emergent Biodefense Operations. He studied at WESTERN KENTUCKY UNIVERSITY between 1980 and 1983 and Clemson University between 1975 and 1979.

Daniel O’Day
Gilead Sciences

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

William Korslin
CCS Medical

William Korslin is a Chief Executive Officer at CCS Medical and is based in Harvard, Illinois. He works or has worked as CEO at Centrad Healthcare LLC.

Joseph Douglas
Genoa

Mr. Luis E. Dini
Home Infusion Solutions

Mr. Luis E. Dini is a Chairman - Chief Executive Officer at Home Solutions and is based in United States.

Mark Evenstad is a Chief Executive Officer at Upsher Smith Laboratories. He works or has worked as President at Upsher Smith Laboratories.

Michael Gavin is a President/CEO at IWP (Injured Workers Pharmacy) and is based in Atlanta, Georgia. He has worked as Senior Manager at Kurt Salmon, VP of Operations at SPH Analytics, and Consultant at Monitor Group. Michael works or has worked as VP:Operations at MDdatacor and President at PRIUM. He studied at Emory University between 2006 and 2007, Emory University - Goizueta Business School between 2006 and 2007, and Georgetown McDonough School of Business between 1997 and 2000.

Imprimis Pharmaceuticals competitors FAQs

Search for jobs